EULAV Asset Management’s Gilead Sciences GILD Stock Holding History

EULAV Asset Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-67,000	Closed	-$5.3M	–	289
2016 Q3	$5.3M	Sell	67,000 -8,000	-11%	-$650K	0.28%	128
2016 Q2	$6.26M	Sell	75,000 -41,000	-35%	-$3.64M	0.34%	102
2016 Q1	$10.7M	Buy	116,000 +6,000	+5%	+$541K	0.59%	57
2015 Q4	$11.1M	Buy	110,000 +1,000	+0.9%	+$104K	0.61%	56
2015 Q3	$10.7M	Buy	109,000 +14,000	+15%	+$1.55M	0.61%	60
2015 Q2	$11.1M	Buy	95,000 +1,000	+1%	+$109K	0.58%	61
2015 Q1	$9.22M	Buy	94,000 +2,000	+2%	+$203K	0.48%	80
2014 Q4	$8.67M	Sell	92,000 -1,000	-1%	-$103K	0.47%	83
2014 Q3	$9.9M	Buy	93,000 +27,000	+41%	+$2.64M	0.54%	63
2014 Q2	$5.47M	Buy	66,000 +10,000	+18%	+$778K	0.29%	119
2014 Q1	$3.97M	Sell	56,000 -7,000	-11%	-$549K	0.22%	159
2013 Q4	$4.73M	Sell	63,000 -24,000	-28%	-$1.67M	0.26%	140
2013 Q3	$5.47M	Sell	87,000 -5,000	-5%	-$299K	0.32%	105
2013 Q2	$4.71M	Buy	+92,000	New	+$4.8M	0.29%	123

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EULAV Asset Management's GILD Position: Q4 2016 in Review

EULAV Asset Management sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 67,000 shares — an estimated $5.3M sold.

EULAV Asset Management first reported a position in GILD in Q2 2013 and held it in 14 quarters. The position peaked at $11.1M in Q4 2015. 1,572 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

EULAV Asset Management reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
EULAV Asset Management sold 67,000 Gilead Sciences shares in Q4 2016, an estimated $5.3M.
EULAV Asset Management first reported a position in Gilead Sciences in Q2 2013 and held it in 14 quarters.
EULAV Asset Management's Gilead Sciences position peaked at $11.1M in Q4 2015.
1,572 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on EULAV Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.